

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

Taro Pharmaceuticals U.S.A., Inc.

Petitioner,

v.

Apotex Technologies, Inc.

Patent Owner

---

Patent No. 7,049,328 B2

Title: USE FOR DEFERIPRONE

---

*Inter Partes* Review No. IPR2017-01446

---

PETITIONER'S UPDATED EXHIBIT LIST

**List of Exhibits for U.S. Patent No. 7,049,328 Petition for *Inter Partes* Review**

<b>Exhibit No.</b>	<b>Description</b>
1001	U.S. Patent No. 7,049,328, Spino et al., <i>Use for Deferiprone</i> , Issued on May 23, 2006, ('328 Patent)
1002	Declaration of Jayesh Mehta, M.D.
1003	Curriculum Vitae of Jayesh Mehta, M.D.
1004	Prosecution History of U.S. Patent No. 7,049,328
1005	Olivieri et al., <i>Reduction of Tissue Iron Stores and Normalization of Serum Ferritin During Treatment with the Oral Iron Chelator L1 in Thalassemia Intermedia</i> , BLOOD, 79(10):2741–48, 1992 (“Olivieri 1992”)
1006	Hoffbrand & Wonke, <i>Iron Chelation Therapy</i> , JOURNAL OF INTERNAL MEDICINE, 242 (Supplement 740): 37–41, 1997 (“Hoffbrand 1997”)
1007	Hoffbrand et al., <i>Long-Term Trial of Deferiprone in 51 Transfusion-Dependent Iron Overloaded Patients</i> , BLOOD, 91(1):295–300, 1998 (“Hoffbrand 1998”)
1008	U.S. Patent No. 5, 922,761, Lai, <i>Methods for In Vivo Reduction of Iron Levels and Compositions Useful Therefor</i> , Issued on July 13, 1999 (“Lai '761”)
1009	Current Index of Medical Specialities, Vol. 21, No. 2, Apr-Jun 1998, CIMS 61 (“CIMS 1998”)
1010	Olivieri et al., <i>First Prospective Randomized Trial of the Iron Chelators Deferiprone (L1) And Deferoxamine</i> , Abstract 983: Hemoglobinopathies and Thalassemias II, 249a, PROGRAM OF THE 37 <sup>TH</sup> ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, December 1995 (“Olivieri Abstract 1995”)

1011	Agarwal, <i>Deferiprone (Kelfer): A Report of 22 Patients Who Have Taken it For Over a Decade</i> , 10 <sup>TH</sup> INTERNATIONAL CONFERENCE ON ORAL CHELATORS IN THE TREATMENT OF THALASSEMIA AND OTHER DISEASES AND BIOMED MEETING, March 2000 (“Agarwal 2000”)
1012	Olivieri et al., <i>Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major</i> , N. ENGL. J. MED., 332:918–22, 1995 (“Olivieri 1995”)
1013	Nathan, <i>Prospective on Thalassemia, Pediatrics</i> , 102(1):281–89, 1998 (“Nathan 1998”)
1014	Olivieri et al., <i>Survival in Medically Treated Patients with Homozygous <math>\beta</math>-Thalassemia</i> , N. ENGL. J. MED., 331:547–78, 1994 (“Olivieri 1994”)
1015	Nathan & Gunn, <i>Thalassemia: The Consequences of Unbalanced Hemoglobin Synthesis</i> , AMERICAN JOURNAL OF MEDICINE, 41:815–30, 1966 (“Nathan 1966”)
1016	Bannerman et al., <i>Thalassemia Intermedia, with Iron Overload, Cardiac Failure, Diabetes Mellitus, Hypopituitarism and Porphyrinuria</i> , AMERICAN JOURNAL OF MEDICINE, 476–86, 1967 (“Bannerman 1967”)
1017	Barman Balfour & Foster, <i>Deferiprone: A Review of its Clinical Potential in Iron Overload in <math>\beta</math>-Thalassemia Major and Other Transfusion-Dependent Diseases</i> , DRUGS 58(3):553–78, 1999 (“Barman Balfour 1999”)
1018	Barry et al., <i>Long-term Chelation Therapy in Thalassemia Major: Effect on Liver Iron Concentration, Liver Histology, and Clinical Progress</i> , BMJ, 2:16–20, 1974 (“Barry 1974”)
1019	Kontoghiorghes, <i>Oral Iron Chelation is Here</i> , BMJ, 303:1279–80, 1991 (“Kontoghiorghes 1991”)
1020	Nathan, <i>An Orally Active Iron Chelator</i> , N. ENGL. J. MED., 332(14):953–54, 1995 (“Nathan 1995”)

1021	GB 2 118 176, <i>Pharmaceutically Active 3-Hydroxypyrid-2-and-4-ones</i> , Published on October 1983 (“Hider Patent”)
1022	Diav-Citrin & Koren, <i>Oral Iron Chelation with Deferiprone</i> , NEW FRONTIERS IN PEDIATRIC DRUG THERAPY, 44(1):235–47, 1997 (“Diav-Citrin 1997”)
1023	Prescribing Information for Ferriprox® (deferiprone) tablets, for oral use (Revised 10/2011) (“Deferiprone Label 2011”)
1024	Olson et al., <i>Endomyocardial Biopsy in Hemochromatosis: Clinicopathologic Correlates in Six Cases</i> , JACC, 13(1):116–20, 1989 (“Olson 1989”)
1025	Kontoghiorghes et al., <i>L1-Deferiprone Worldwide Update and New Strategies for Improving its Therapeutic Efficiency</i> , 10 <sup>TH</sup> INTERNATIONAL CONFERENCE ON ORAL CHELATORS IN THE TREATMENT OF THALASSEMIA AND OTHER DISEASES AND BIOMED MEETING, March 2000 (“Kontoghiorghes 2000”)
1026	Faa & Crisponi, <i>Iron Chelating Agents in Clinical Practice</i> , COORDINATION CHEMISTRY REVIEWS, 184:291–310, 1999 (“Faa 1999”)
1027	Borgna-Pignatti, <i>Survival and Disease Complications in Thalassaemia Major</i> , ANNALS NEW YORK ACADEMY OF SCIENCES, 227–31, 1998 (“Borgna-Pignatti 1998”)
1028	McDonald, <i>Deferoxamine and Diethylenetriaminepentaacetic Acid (DTPA) in Thalassaemia</i> , THE JOURNAL OF PEDIATRICS 69(4):563–71, 1966 (“McDonald 1966”)
1029	Cerami, <i>“Propper” Use of Desferrioxamine</i> , N. ENGL. J. MED, 294(26): 1456-57, 1976 (“Cerami 1976”)
1030	European Patent Register Opposition to EP1294379, A New Use for Deferiprone, Application published on January 10, 2002
1031	Morrison, <i>Diagnosis and Management of Hereditary Hemochromatosis</i> , JOURNAL OF CLIN. OUTCOMES MANAGEMENT, Vol 6, No. 5, (1999). (“Morrison”)

1032	Kratz, <i>Normal Reference Laboratory Values</i> , NEW ENGLAND JOURNAL OF MEDICINE, Vol. 339, No. 15 (1998) (“Kratz”).
1033	Mehta et al., <i>Deaths in Patients Receiving Oral Iron Chelator LI</i> , BR. J. HAEMATOL., 85:430–31, 1993
1034	Mehta et al., <i>Deferiprone in Iron Overload</i> , N. ENGL. J. MED., 333:597–99, 1995
1035	Mehta et al., <i>Oral Iron Chelator LI and Autoimmunity</i> , BLOOD, 81:1970–71, 1993
1036	March 23, 2018 Telephonic Hearing Transcript PROTECTIVE ORDER MATERIAL
1037	October 8, 2009 Letter from ApoPharma to FDA PROTECTIVE ORDER MATERIAL
1038	October 7, 1999 Email from M. Spino to F. Tricta with attachments PROTECTIVE ORDER MATERIAL
1039	October 8, 1999 Email from F. Tricta to M. Spino with attachment PROTECTIVE ORDER MATERIAL
1040	April 3, 2000 Email from M. Spino to J. Furedy, copying F. Tricta with attachment PROTECTIVE ORDER MATERIAL
1041	January 1, 2000 Email from M. Spino to S. Mandell with attachments PROTECTIVE ORDER MATERIAL
1042	November 8, 2017 Deposition Transcript of Michael Spino PROTECTIVE ORDER MATERIAL
1043	November 7, 2017 Deposition Transcript of Fernando Tricta, M.D. PROTECTIVE ORDER MATERIAL
1044	Opening Expert Report of Thomas D. Coates, M.D. PROTECTIVE ORDER MATERIAL
1045	Opening Expert Report of Dudley J. Pennell, M.D. PROTECTIVE ORDER MATERIAL
1046	Intentionally Left Blank
1047	MODULE 2, SECTION 2.7.3, SUMMARY OF CLINICAL EFFICACY FOR FERRIPROX® (deferiprone) PROTECTIVE ORDER MATERIAL
1048	MODULE 2, SECTION 2.7.5, LITERATURE REFERENCES FOR FERRIPROX® (deferiprone) PROTECTIVE ORDER MATERIAL

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.